Подписаться
Юрій Степанович Рудик
Юрій Степанович Рудик
ДУ “Нацiональний iнститут терапії iменi Л.Т. Малої Національної академії медичних наук України” / L
Подтвержден адрес электронной почты в домене amnu.gov.ua
Название
Процитировано
Процитировано
Год
Edoxaban versus warfarin in patients with atrial fibrillation
RP Giugliano, CT Ruff, E Braunwald, SA Murphy, SD Wiviott, JL Halperin, ...
New England Journal of Medicine 369 (22), 2093-2104, 2013
58942013
Evolocumab and clinical outcomes in patients with cardiovascular disease
MS Sabatine, RP Giugliano, AC Keech, N Honarpour, SD Wiviott, ...
New England journal of medicine 376 (18), 1713-1722, 2017
57662017
Telmisartan, ramipril, or both in patients at high risk for vascular events
Ontarget Investigators
New England Journal of Medicine 358 (15), 1547-1559, 2008
49572008
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
K Swedberg, M Komajda, M Böhm, JS Borer, I Ford, A Dubost-Brama, ...
The Lancet 376 (9744), 875-885, 2010
33542010
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)
MD Flather, MC Shibata, AJS Coats, DJ Van Veldhuisen, A Parkhomenko, ...
European heart journal 26 (3), 215-225, 2005
23362005
Long-term use of ticagrelor in patients with prior myocardial infarction
MP Bonaca, DL Bhatt, M Cohen, PG Steg, RF Storey, EC Jensen, ...
New England Journal of Medicine 372 (19), 1791-1800, 2015
21702015
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
RR Holman, MA Bethel, RJ Mentz, VP Thompson, Y Lokhnygina, JB Buse, ...
New England Journal of Medicine 377 (13), 1228-1239, 2017
20162017
Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial
J Rosenstock, V Perkovic, OE Johansen, ME Cooper, SE Kahn, N Marx, ...
Jama 321 (1), 69-79, 2019
11122019
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
H Haller, S Ito, JL Izzo Jr, A Januszewicz, S Katayama, J Menne, ...
New England Journal of Medicine 364 (10), 907-917, 2011
10842011
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors
MR Weir, GL Bakris, DA Bushinsky, MR Mayo, D Garza, Y Stasiv, J Wittes, ...
New England Journal of Medicine 372 (3), 211-221, 2015
6902015
Ivabradine in stable coronary artery disease without clinical heart failure
K Fox, I Ford, PG Steg, JC Tardif, M Tendera, R Ferrari
New England Journal of Medicine 371 (12), 1091-1099, 2014
6262014
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study
KK Ray, B Molemans, WM Schoonen, P Giovas, S Bray, G Kiru, J Murphy, ...
European journal of preventive cardiology 28 (11), 1279-1289, 2021
5892021
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized …
M Jadzinsky, A Pfützner, E Paz‐Pacheco, Z Xu, E Allen, R Chen, ...
Diabetes, Obesity and Metabolism 11 (6), 611-622, 2009
3952009
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
DE Low, TM File Jr, PB Eckburg, GH Talbot, H David Friedland, J Lee, ...
Journal of antimicrobial chemotherapy 66 (suppl_3), iii33-iii44, 2011
2192011
Cause of death and predictors of all‐cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF
SD Pokorney, JP Piccini, SR Stevens, MR Patel, KS Pieper, JL Halperin, ...
Journal of the American Heart Association 5 (3), e002197, 2016
1592016
REDUCE-IT USA: results from the 3146 patients randomized in the United States
DL Bhatt, M Miller, EA Brinton, TA Jacobson, PG Steg, SB Ketchum, ...
Circulation 141 (5), 367-375, 2020
1412020
The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction–baseline characteristics of the …
VM Maria da Consolação, S Heringer-Walther, N Wessel, TM Ventura, ...
Cardiology 110 (4), 271-282, 2008
932008
Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation: Results from the GARFIELD-AF registry
JP Bassand, S Virdone, SZ Goldhaber, AJ Camm, DA Fitzmaurice, ...
Circulation 139 (6), 787-798, 2019
89*2019
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
MP Schlaich, M Bellet, MA Weber, P Danaietash, GL Bakris, JM Flack, ...
The Lancet 400 (10367), 1927-1937, 2022
882022
Angina and future cardiovascular events in stable patients with coronary artery disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry
A Eisen, DL Bhatt, PG Steg, KA Eagle, S Goto, J Guo, SC Smith, ...
Journal of the American Heart Association 5 (10), e004080, 2016
822016
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20